Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.37 |
| ▸ | IP6K3 | Q96PC2 | 2/20 | 0.37 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 11/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 2/20 | 0.32 |
| ▸ | CCND1 | P24385 | 2/20 | 0.32 |
| ▸ | CCND2 | P30279 | 2/20 | 0.32 |
| ▸ | CCND3 | P30281 | 2/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886894 | 0.88 | HRH3 (0.40) | CNR2HRH3 | |
| SCHEMBL5887290 | 0.83 | ALDH1A1 (0.44) | — | |
| SCHEMBL5886693 | 0.81 | MAPK8 (0.38) | CNR2 | |
| SCHEMBL5887184 | 0.81 | CHEK1 (0.46) | CDK4CCND1CCND2CCND3 | |
| SCHEMBL5886887 | 0.81 | BRAF (0.42) | CNR2 | |
| SCHEMBL5887095 | 0.81 | ALDH1A1 (0.44) | — | |
| SCHEMBL5887089 | 0.80 | GPR119 (0.32) | GPR119HRH3KDM1A | |
| SCHEMBL5887036 | 0.80 | EPHX2 (0.39) | GPR119 | |
| SCHEMBL5887545 | 0.80 | HSD11B1 (0.40) | — | |
| SCHEMBL5887189 | 0.80 | SMN1; SMN2 (0.44) | CNR2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | GPR119 4543/4885IP6K1 416/4885IP6K3 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.